Introduction
============

Both estrogen (E) and testosterone (T) are critical regulators of bone turnover, but the precise mechanisms by which these sex steroids have their effects on bone remain unclear. In women, E clearly reduces bone resorption,([@b1]) and this effect is mediated by an inhibition of osteoclast development and activity, as well as increased osteoclast apoptosis (for review, see ref. 2). Effects of E on bone formation have been more difficult to define. E deficiency is associated with an increase in bone remodeling,([@b3]) and the associated increase in bone resorption is accompanied by a coupled increase in bone formation at the tissue level.([@b2]) However, at each basic multicellular unit (BMU) there remains a gap between bone resorption and bone formation, with formation unable to keep up with resorption, resulting in a net loss of bone.([@b2]) By inference, therefore, sex steroid deficiency is associated with a defect in bone formation. Consistent with this, several studies now demonstrate that acute (3 to 4 weeks) E withdrawal([@b4]) or treatment([@b5]) results in a decrease and increase, respectively, in bone-formation markers, reflecting the underlying effects of E in maintaining bone formation at the cellular level. However, chronic E treatment of postmenopausal women is associated with reduced bone-resorption markers, leading, owing to the "coupling" of bone resorption and bone formation, to a reduction in bone-formation markers.([@b1],[@b5]) Studies in rats also have found that histologic bone-formation rates decrease early (at 5 days) following ovariectomy, but owing to the coupling with the increase in bone resorption, bone-formation rates are elevated 2 to 3 weeks following ovariectomy.([@b6]) Thus, at the cellular level, E is important for the maintenance of bone formation in part due to a reduction in osteoblast apoptosis.([@b7])

Studies in men also have demonstrated a critical role for E in suppressing bone resorption and in maintaining bone formation.([@b8]--[@b10]) Effects of E appear to be dominant over those of T, at least for bone resorption.([@b8]) T effects on maintaining bone formation in humans appear to vary depending on the bone-formation marker used. We previously found that decreases in serum N-terminal propeptide of type 1 collagen (P1NP) levels following acute (3 weeks) E and T deficiency in men were prevented by E but not T, whereas both E and T were able to prevent decreases in serum osteocalcin (OCN) levels.([@b8])

The identification of the Wnt/β-catenin signaling pathway as a major regulator of bone mass([@b11],[@b12]) has led to considerable interest in potential crosstalk between this pathway and sex steroid signaling.([@b13]) A major regulator of Wnt signaling is sclerostin, which is a secreted Wnt antagonist produced by osteocytes that regulates bone mass by binding to low-density lipoprotein receptor-related protein (LRP)5 and LRP6 to inhibit the canonical Wnt/β-catenin signaling pathway. The biologic importance of sclerostin in regulating bone mass in humans is highlighted by two genetic disorders associated with markedly increased bone mass: sclerosteosis and van Buchem disease.([@b14]--[@b17]) These findings, combined with the demonstration that sclerostin-deficient mice have increased bone mass,([@b18]) have led to the development of antisclerostin neutralizing antibodies as a novel anabolic treatment for osteoporosis.([@b19])

The recent development of immunoassays for sclerostin led to the observation by Mirza and colleagues([@b20]) that postmenopausal women had higher serum sclerostin levels than premenopausal women, and in postmenopausal women, serum sclerostin levels were inversely associated with the circulating free estradiol (E~2~) index. These findings suggest that E may regulate sclerostin production; however, correlation does not prove causality, so in this study we tested the possible regulation by E of circulating sclerostin levels in women and in men. In addition, in the men, we also compared effects of E versus T on serum sclerostin levels and in both sexes related changes in sclerostin levels following hormonal manipulations to changes in bone turnover markers.

Methods
=======

Study subjects and experimental protocol
----------------------------------------

### Study A: Women

Serum samples for the sclerostin measurements were from a previous study from our group.([@b21]) Briefly, 34 early postmenopausal women aged 40 to 65 years were randomized into an open-label, controlled study to receive E treatment or no treatment for 4 weeks. Menopausal status was defined by the absence of menses for more than 1 year in a woman over 50 years of age, and in women with previous hysterectomy or those under 50 years of age, an elevated value for serum follicle-stimulating hormone (FSH) was required. All women were healthy and had no clinically significant abnormalities in laboratory values and no diseases known to affect bone metabolism, and they were not taking any drug known to affect bone turnover. All subjects provided full informed consent, and the study was approved by the Mayo Clinic Institutional Review Board. Details regarding ensuring vitamin D sufficiency in the study subjects have been described previously.([@b21]) Subjects randomized to E treatment (*n* = 17) received 17β-estradiol (17β-E~2~, 100 µg/day) by cutaneous patches (Vivelle, Novartis, East Hanover, NJ, USA) that were changed every 3 to 4 days for 4 weeks. Fasting (8 a.m.) serum samples were drawn at baseline and at 28 days of treatment (or no treatment in the control group). Serum samples were frozen and stored at −80°C, and only previously unthawed samples were used in all analyses in this study.

### Study B: Men

The samples for this study were derived from a previously published study on the regulation of bone turnover by sex steroids in men.([@b10]) Briefly, 59 elderly men aged 50 to 80 years were recruited for the study. As for study A, all men were healthy and had no clinically significant abnormalities in laboratory values, no diseases known to affect bone metabolism, and were not taking any drug known to affect bone turnover. All subjects provided full informed consent, and the study was approved by the Mayo Clinic Institutional Review Board. Details regarding ensuring vitamin D sufficiency in these study subjects also have been described previously.([@b10])

At the time of entry into the study, the subjects were administered a long-acting gonadotropin-releasing hormone (GnRH) agonist \[leuprolide acetate (Lupron-Depot), TAP Pharmaceuticals, Deerfield, IL, USA\], 7.5 mg intramuscularly, to suppress endogenous T and E production. They also were started on the aromatase inhibitor \[letrozole (Femara), Novartis\], 2.5 mg/day. Physiologic T and E~2~ levels were maintained by starting the subjects on a T gel (AndroGel, Solvay Pharmaceuticals, Marietta, GA, USA), 5 g/day (delivering 5 mg/day of T), as well as an E~2~ patch (VivelleDot, Novartis), 37.5 µg/day. After 3 weeks following GnRH agonist administration and while maintaining letrozole, T, and E~2~ treatment, the subjects were admitted to the Mayo Clinical Research Unit (CRU) for their baseline visit. After an overnight fast, serum samples were drawn at 8 a.m. for the study assays. Following the baseline studies, the subjects were randomized into one of four groups: group A (--T, --E; *n* = 15) discontinued both T and E replacement, group B (--T, +E; *n* = 15) discontinued the T gel but continued the E patch, group C (+T, --E; *n* = 15) discontinued the E patch but continued the T gel, and Group D (+T, +E, *n* = 14) continued both the T gel and the E patch. All subjects received a second dose of the GnRH agonist, and all subjects continued letrozole treatment throughout the study period. Three weeks following randomization, the subjects were readmitted to the CRU for their final visit, and repeat fasting (8 a.m.) blood samples were obtained. As for study A, serum samples were frozen and stored at --80°C, and only previously unthawed samples were used in all analyses in this study.

Hormonal and biochemical assays
-------------------------------

Serum calcium and phosphorus concentrations were measured by an automated photometric assay \[interassay coefficient of variation (CV) \< 10%; Roche Diagnostics, Madison, WI, USA\]. Serum creatinine was measured using an automated enzymatic colorimetric assay (interassay CV \< 10%; Roche Diagnostics). Serum 25-hydroxyvitamin D \[25(OH)D\] was measured using tandem mass spectroscopy (interassay CV \< 7%; API 5000, Applied Biosystems-MDS Sciex, Carlsbad, CA, USA). Serum P1NP was measured by radioimmunassay \[interassay CV \< 10%; Immunodiagnostic Systems (IDS, Scotsdale, AZ, USA)\], and serum osteocalcin (OCN) was measured using a two-site immunoradiometric assay (interassay CV \< 8%; CIS-US, Bedford, MA, USA). Serum C-terminal telopeptide of type I collagen (CTX) was measured by ELISA (interassay CV \< 8%; IDS), and serum tartrate-resistant acid phosphatase isoform type 5b (TRACP5b) also was measured by ELISA (interassay CV \< 14%; IDS), as was serum osteoprotegerin (OPG; interassay CV \< 8%; ALPCO Immunoassays, Salem, NH, USA).

To measure serum sclerostin levels, we used two different immunoassays in study A, an in-house assay and a commercial assay. Because we observed similar changes with the two assays, only the commercial assay was used in study B. For the in-house assay, we used an ELISA developed in our laboratory. A biotinylated goat antihuman sclerostin antibody (R&D Systems, Minneapolis, MN, USA) was added to streptavidin-coated plates followed by the samples and standards (recombinant human sclerostin, R&D Systems). After a 3-hour incubation, a monoclonal antihuman sclerostin antibody (R&D Systems) was added. Following a 1-hour incubation, antimouse IgG--horseradish peroxidase was added for 30 minutes. The plate was washed for a final time, substrate was added for 30 minutes, and the plate was read at 450/620. The interassay CV was 8%, and the lower limit of detection was 100 pg/mL. For the commercial assay, we used a recently available quantitative sandwich ELISA obtained from ALPCO (developed by Biomedica, Vienna, Austria).([@b22]) The interassay CV was 4%, and the lower limit of detection was 86 pg/mL.

Statistical analysis
--------------------

For study A, the comparisons between the control and E-treated women were made using two-sample, two-sided *t* tests. For study B, as described previously,([@b8],[@b10]) the primary method of analysis to dissect out effects of E versus T on the various parameters took advantage of the factorial design. Thus we used a two-factor ANOVA model to compare the changes in the variables in the +E (groups B and D) versus--E (groups A and C) and +T (groups C and D) versus--T (groups A and C) groups (essentially pooling the two --E and two +E groups for comparison and similarly for the --T and +T groups). For both studies, the relationships between various variables of interest were defined using the Pearson correlation. A one-sample, two-sided *t* test was used to assess percent changes from baseline for variables where we had baseline and final measurements. Results were considered significant at the *p* \< .05 level.

Results
=======

Baseline parameters in study subjects
-------------------------------------

[Table 1](#tbl1){ref-type="table"} shows the baseline anthropometric and biochemical variables in the study subjects. As is evident, for both studies, the subjects in the various groups were well matched for all these variables. Similarly, bone turnover markers and serum sclerostin levels (measured using both the in-house and commercial assays in the women but only the commercial assay in the men) were similar across all study groups at baseline ([Table 2](#tbl2){ref-type="table"}).

###### 

Baseline Anthropometric and Biochemical Parameters in the Study Subjects

  Study A: Women                                               
  -------------------------------- ------------- ------------- ------
  *N*                              18            17            
  Age, years                       54 ± 1        54 ± 1        .902
  Height, m                        1.67 ± 0.01   1.63 ± 0.02   .047
  Weight, kg                       76.2 ± 3.7    74.7 ± 3.0    .762
  Body mass index (BMI), kg/m^2^   27.4 ± 1.3    28.3 ± 1.3    .592
  Serum parameters                                             
   Ca, mg/dL                       9.7 ± 0.1     9.7 ± 0.1     .692
   Phosphorus, mg/dL               3.7 ± 0.1     3.9 ± 0.1     .335
   Cr, mg/dL                       1.0 ± 0.03    0.9 ± 0.03    .204
   25(OH)D, ng/mL                  31.3 ± 2.1    33.5 ± 1.6    .425

  Study B: Men                                                                  
  --------------------- ------------- ------------- ------------- ------------- -------
  *N*                   15            15            15            14            
  Age, years            66 ± 3        66 ± 2        70 ± 1        66 ± 3        0.603
  Height, m             1.76 ± 0.01   1.77 ± 0.03   1.79 ± 0.02   1.79 ± 0.02   0.701
  Weight, kg            87.3 ± 2.9    86.7 ± 3.4    88.4 ± 2.3    90.0 ± 3.3    0.879
  BMI, kg/m^2^          28.1 ± 1.0    27.7 ± 0.9    27.7 ± 0.7    28.1 ± 0.9    .959
  Serum parameters                                                              
   Ca, mg/dL            9.4 ± 0.1     9.6 ± 0.1     9.4 ± 0.1     9.4 ± 0.1     .318
   Phosphorous, mg/dL   3.4 ± 0.1     3.5 ± 0.1     3.3 ± 0.1     3.1 ± 0.1     .128
   Cr, mg/dL            1.1 ± 0.03    1.2 ± 0.04    1.1 ± 0.03    1.2 ± 0.03    .189
   25(OH)D, ng/mL       31.1 ± 1.6    28.3 ± 2.2    32.1 ± 2.5    32.2 ± 2.5    .579

For comparison of control and estrogen groups.

For comparison of all four groups by ANOVA.

###### 

Baseline Bone Turnover Markers and Sclerostin Levels in the Study Subjects

  Study A: Women                                                     
  -------------------------------------- ------------- ------------- ------
  P1NP, µg/L                             47.9 ± 3.2    58.3 ± 7.0    .174
  OCN, ng/mL                             29.8 ± 2.2    28.8 ± 2.1    .745
  CTX, ng/mL                             0.73 ± 0.06   0.74 ± 0.08   .936
  TRACP5b, U/L                           4.0 ± 0.3     4.2 ± 0.3     .716
  Sclerostin (in-house assay), pg/mL     579 ± 67      555 ± 55      .782
  Sclerostin (commercial assay), pg/mL   312 ± 21      302 ± 19      .731

  Study B: Men                                                                                  
  -------------------------------------- ------------- ------------ ------------- ------------- ------
  P1NP, µg/L                             38.6 ± 3.2    43.5 ± 5.5   40.4 ± 3.2    41.9 ± 5.5    .880
  CTX, ng/mL                             0.54 ± 0.05   0.55 ± 0.8   0.50 ± 0.05   0.54 ± 0.07   .940
  TRACP5b, U/L                           3.8 ± 0.3     2.9 ± 0.2    3.4 ± 0.3     3.1 ± 0.3     .085
  Sclerostin (commercial assay), pg/mL   439 ± 33      446 ± 44     406 ± 29      447 ± 47      .861

For comparison of control and estrogen groups.

For comparison of all four groups by ANOVA.

Changes in bone turnover markers and in sclerostin levels following hormonal manipulations
------------------------------------------------------------------------------------------

[Table 3](#tbl3){ref-type="table"} shows the percent changes from baseline in bone turnover markers in the study subjects. As has been described before for the early effects of E treatment on bone-formation markers,([@b5]) 4 weeks of E treatment in the women (study A) led to significant increases in bone-formation markers (P1NP and OCN) and decreases in bone-resorption markers (CTX and TRACP5b). As shown in [Fig. 1](#fig01){ref-type="fig"}, these changes were accompanied by significant reductions in serum sclerostin levels using both the in-house and commercial assays. Using data from both groups combined, the percent change in serum sclerostin levels using the in-house assay were significantly correlated with the percent changes in serum sclerostin levels using the commercial assay (*r* = 0.76, *p* \< .0001). However, the percent changes in serum P1NP or OCN levels did not correlate with percent changes in sclerostin levels using either assay (*r* = 0.15, *p* = .410, and *r* = --0.08, *p* = .649 for P1NP and OCN, respectively, for the in-house assay, and *r* = --0.06, *p* = .754, and *r* = --0.10, *p* = .563, for P1NP and OCN, respectively, for the commercial assay). Of interest, however, the percent change in serum CTX did correlate significantly with changes in sclerostin levels using either the in-house ([Fig. 2*A*](#fig02){ref-type="fig"}) or commercial assay ([Fig. 2*B*](#fig02){ref-type="fig"}), with similar correlations for TRACP5b ([Fig. 2*C, D*](#fig02){ref-type="fig"}).

###### 

Percent Changes from Baseline in Bone Turnover Markers in the Study Subjects Following the Hormonal Manipulations

  Study A: Women                                                                   
  ---------------- ------------ -------------------------------------------------- --------
  P1NP             12.2 ± 6.4   42.1 ± 9.3[\*\*\*](#tf3-3){ref-type="table-fn"}    .012
  OCN              −2.0 ± 2.7   6.6 ± 2.8[\*](#tf3-1){ref-type="table-fn"}         .034
  CTX              −7.5 ± 5.2   −36.8 ± 3.0[\*\*\*](#tf3-3){ref-type="table-fn"}   \<.001
  TRACP5b          −2.6 ± 2.1   −25.3 ± 2.2[\*\*\*](#tf3-3){ref-type="table-fn"}   \<.001

  Study B: Men                                                                                                                                                                              
  -------------- ------------------------------------------------- ----------------------------------------------- -------------------------------------------------- ------------ -------- ------
  P1NP           −13.4 ± 4.9[\*](#tf3-1){ref-type="table-fn"}      −8.3 ± 2.3[\*\*](#tf3-2){ref-type="table-fn"}   −17.4 ± 2.9[\*\*\*](#tf3-3){ref-type="table-fn"}   −3.7 ± 2.9   .015     .486
  CTX            56.3 ± 14.3[\*\*](#tf3-2){ref-type="table-fn"}    14.2 ± 7.3                                      53.3 ± 14.1[\*\*](#tf3-2){ref-type="table-fn"}     10.2 ± 7.9   \<.001   .760
  TRACP5b        16.7 ± 2.4[\*\*\*](#tf3-3){ref-type="table-fn"}   5.9 ± 3.1                                       17.2 ± 3.4[\*\*\*](#tf3-3){ref-type="table-fn"}    2.6 ± 1.5    \<.001   .614

*Note:* For each group (eg, Men, --T, --E), the baseline values for each marker for that group, as shown in [Table 2](#tbl2){ref-type="table"}, were used to calculate percent changes.

*p* \< .05

*p* \< .01

*p* \< .001 versus baseline.

*p* Value for comparison of the change in the E versus the control groups.

*p* Value using a two-factor ANOVA model for E or T effects.

![Percent change from baseline in serum sclerostin levels in the subjects in study A using either the in-house assay (*open bars*) or the commercial assay (*solid bars*). *p* Values for differences in changes in the control versus E-treated groups are as indicated. \*\*\**p* \< .001 for significance of change from baseline.](jbmr0026-0027-f1){#fig01}

![Correlations between percent changes in serum CTX in the two groups of women in study A combined versus percent change in serum sclerostin levels using either the in-house (*A*) or commercial (*B*) assay. Panels *C* and *D* show the analogous relationships for TRACP5b versus sclerostin using either the in-house assay or commercial assay, respectively.](jbmr0026-0027-f2){#fig02}

[Table 3](#tbl3){ref-type="table"} also shows the changes in bone turnover markers in the men (study B) following their hormonal manipulations. As reported previously([@b8],[@b10]) with acute sex steroid deficiency (--T, --E), serum P1NP levels decreased significantly in the men, and this decrease was attenuated by E, but not by T, treatment. Conversely, bone-resorption markers increased significantly following sex steroid deficiency, and these increases were prevented by E, but not by T, treatment. Given that the in-house and commercial sclerostin assays performed very similarly in the women ([Fig. 1](#fig01){ref-type="fig"}), we only used the commercial assay in men, and [Fig. 3](#fig03){ref-type="fig"} shows the percent changes from baseline in serum sclerostin levels in the four groups of men. As is evident, serum sclerostin levels increased following sex steroid deficiency in the --T, --E group; decreased significantly in the --T, +E group; increased significantly in the +T, --E group; and did not change in the sex steroid--sufficient group (+T, +E). Using the two-factor ANOVA model, there was a highly significant E effect (*p* \< .001) on reducing sclerostin levels and a borderline significant (*p* = .052) T effect on increasing sclerostin levels, suggesting opposite effects of E versus T on sclerostin levels. Similar to the findings in the women, percent changes in serum P1NP levels in the four groups combined did not correlate with changes in sclerostin levels (*r* = 0.05, *p* = .693). However, as in the women, changes in serum CTX and in TRACP5b did correlate significantly with changes in sclerostin levels (*r* = 0.33, *p* = .009, and *r* = 0.32, *p* = .014, for CTX and TRACP5b, respectively).

![Percent change from baseline in serum sclerostin levels in the subjects in study B. The *p* values for the E and T effects are based on the two-factor ANOVA model described under "Methods." Briefly, this compares changes in the +E versus --E groups for the E effect and changes in the +T versus the --T groups for the T effect. \**p* \< .05, \*\**p* \< .01, and ^†^*p* = .051 for significance of change from baseline.](jbmr0026-0027-f3){#fig03}

Since previous studies have demonstrated that *OPG* is a Wnt target gene,([@b23]) we tested whether the observed correlations between changes in serum sclerostin levels and bone resorption markers were accompanied by parallel changes in serum OPG levels. [Table 4](#tbl4){ref-type="table"} shows the baseline OPG levels in the subjects in the two studies, as well as changes following the hormonal manipulations. As is evident, there were no significant changes in serum OPG levels in any of the groups. Moreover, changes in sclerostin levels did not correlate with changes in OPG levels either in study A or study B (data not shown).

###### 

Baseline and Percent Changes in Serum OPG Levels in the Study Subjects Following the Hormonal Manipulations

  Study A: Women                             
  ---------------- ------------ ------------ ------
  OPG, pmol/L      3.4 ± 0.4    3.0 ± 0.3    .463
  OPG, % change    −1.6 ± 4.5   −6.7 ± 5.0   .448

  Study B: Men                                                   
  -------------- ----------- ----------- ----------- ----------- -------
  OPG, pmol/L    2.9 ± 0.2   2.9 ± 0.2   2.6 ± 0.1   2.8 ± 0.3   0.624

                                                                    E effect   T effect
  --------------- ----------- ----------- ------------ ------------ ---------- ----------
  OPG, % change   3.8 ± 3.5   1.6 ± 5.3   −2.8 ± 3.3   −2.1 ± 3.7   .842       .207

*Note:* For each group, the percent changes were calculated using the respective baseline values.

\* *p* \< .05; \*\**p* \< .01; \*\*\**p* \< .001 versus baseline.

*p* Value for comparison of baseline values or the percent change in the E versus the control groups.

*p* Value for comparison of four groups at baseline by ANOVA or for E or T effects using a two-factor ANOVA model.

Discussion
==========

Using two different study designs (E treatment versus E withdrawal) and in both women and men, we demonstrate in this study that E treatment reduces, whereas E withdrawal increases, serum sclerostin levels. These data clearly establish that circulating sclerostin levels and, presumably, sclerostin production by osteocytes in bone are regulated by E. Our findings are consistent with the recent observation by Mirza and colleagues([@b20]) that serum sclerostin levels are inversely associated with the free E~2~ index in postmenopausal women. However, using direct interventions, our data provide proof of causality, which only can be inferred by correlations. While our studies do not establish whether E regulates sclerostin production directly or indirectly, Huang and colleagues([@b24]) recently have identified a --9247 T/C polymorphism in the *SOST* upstream regulatory region that is associated with spine, femoral neck, trochanter, and total hip bone mineral density (BMD) and is located at the core consensus recognition site of two cooperating transcription factors, C/EBPα and FOXA1, that modulate E receptor (ER) function. Thus C/EBPα has been shown to interact with ERα in glutathione-*S*-transferase pull-down experiments,([@b25]) and knock-down of *FOXA1* expression has been shown to block the association of the ER with chromatin and expression of E-induced genes.([@b26],[@b27]) Moreover, the *SOST* promoter has three additional classical E-response elements between the --9247 polymorphism and the transcriptional start site.([@b24]) As such, the *SOST* gene may be a direct target for E, but clearly, further studies are needed to address whether E regulates *SOST* expression at a transcriptional level.

In contrast to E, our data in study B indicate that T (in the absence of aromatization to E) fails to suppress, and appears to increase, circulating sclerostin levels. While T previously has been thought of as being "anabolic" for bone, direct evidence for this is relatively sparse.([@b2]) On the contrary, males with mutations either in the *ERα* gene([@b28],[@b29]) or in the gene encoding aromatase([@b30],[@b31]) have marked deficits in bone mass despite having normal or elevated T levels. The biologic significance of the apparent stimulatory effects of T on circulating sclerostin levels, however, needs to be defined by additional studies in humans and animal models.

In study A, we used two independent sclerostin assays to evaluate changes following E treatment, with virtually identical results. The fact that we got the same results using independently generated antibodies to sclerostin (R&D Systems and Biomedica) provides further confidence that our observations are valid independent of the sclerostin antibody used in the assays. However, since the commercial assay is easier to perform and has greater precision than our in-house assay, we used the commercial assay in study B.

Perhaps somewhat surprising was our finding that changes in sclerostin levels in both studies failed to correlate with changes in bone-formation markers but did correlate with changes in bone-resorption markers. The lack of correlation with the bone-formation markers could be due to several reasons: First, changes in sclerostin may account for only part of the effects of E in maintaining bone formation, given the known multiple pathways regulated by E that could have an impact on bone formation.([@b2],[@b32]) In addition, it is possible that changes in sclerostin production occur well before changes in bone-formation markers, and even sampling sclerostin levels 3 to 4 weeks following E treatment or withdrawal may have missed more robust changes in serum sclerostin levels early after changes in E status, which also might have shown stronger associations with the bone-formation markers. It is also possible that changes in peripheral sclerostin levels may not fully reflect alterations in sclerostin production in the bone microenvironment; however, we have found recently ([@b33]) that circulating sclerostin levels are highly correlated with bone marrow plasma sclerostin levels, suggesting that peripheral sclerostin levels likely do accurately reflect sclerostin levels in the bone microenvironment.

In contrast to the bone-formation markers, changes in circulating sclerostin levels did correlate with changes in the bone-resorption markers. These findings are consistent with a recent study in rats showing that treatment of ovariectomized rats with a neutralizing antibody to sclerostin not only increased bone-formation rates but also reduced osteoclast numbers on bone surfaces.([@b19]) Similarly, treatment of postmenopausal women for up to 85 days with an antisclerostin antibody also resulted in an increase in bone-formation markers as well as a decrease in bone-resorption markers.([@b34]) These data in rats and humans are entirely consistent with our findings, and increasing evidence now indicates that changes in sclerostin activity regulate not only bone formation but also bone resorption. Since *OPG* is a known Wnt target gene,([@b23]) we also tested whether the association between changes in sclerostin levels and changes in bone-resorption markers could be explained by alterations in circulating OPG levels. However, this was not the case, and these findings would suggest that mechanisms other than regulation of OPG may account for the relationship between sclerostin levels and bone-resorption markers, although we cannot exclude the possibility that the lack of changes in serum OPG levels were related to our relatively small sample size and/or the fact that OPG is produced by a number of nonskeletal tissues.([@b35]) As such, serum OPG levels may not reflect changes in the bone microenvironment. Nonetheless, it is of interest that Wnt signaling has been implicated recently in regulating not only bone formation but also bone resorption. Thus activation of Wnt signaling has been shown to downregulate *RANKL* mRNA and protein expression in osteoblasts([@b36]) and to directly inhibit the differentiation of osteoclast precursor cells through the canonical pathway.([@b37],[@b38])

While our findings are consistent with E regulation of sclerostin production in humans, we recognize that there is currently no information on the stability of sclerostin or its degradation in the circulation. Thus we cannot exclude an effect of E on the metabolism of sclerostin; further studies addressing this issue and, as noted earlier, examining possible direct transcriptional regulation of the *SOST* gene by E need to be done.

In summary, our studies demonstrate that in both sexes, E decreases circulating sclerostin levels. While the reduction in sclerostin production may play a role in the effects of E in maintaining bone formation, the associations we observed between changes in sclerostin levels and in bone-resorption markers suggest that at least part of the antiresorptive effects of E also may be mediated via changes in sclerostin production. Our findings thus identify sclerostin as a potentially important mediator of E effects on bone turnover, and further human and animal studies are needed to more precisely define how much of the overall E effect on bone formation and resorption can be explained by changes in sclerostin production.
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